Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | HTR2B | P41595 | 2/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19207191 | 0.92 | HRH3 (0.45) | HRH3CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL188648 | 0.91 | HRH3 (0.63) | HRH3SMN1; SMN2CHRM1CHRM2 | |
| SCHEMBL714763 | 0.81 | SMN1; SMN2 (0.59) | HRH3SMN1; SMN2CHRM4CHRM5CHRM1 | |
| SCHEMBL14578240 | 0.81 | HRH3 (0.56) | HRH3SMN1; SMN2CHRM4CHRM5CHRM1 | |
| SCHEMBL10261345 | 0.81 | SMN1; SMN2 (0.59) | HRH3SMN1; SMN2CHRM4CHRM5CHRM1 | |
| SCHEMBL10262302 | 0.81 | SMN1; SMN2 (0.59) | HRH3SMN1; SMN2CHRM4CHRM5CHRM1 | |
| SCHEMBL24596869 | 0.80 | HRH3 (0.54) | HRH3SMN1; SMN2CHRM4CHRM5CHRM1 | |
| SCHEMBL15830259 | 0.80 | HTR2C (0.59) | HRH3SMN1; SMN2HTR2CHTR2BACACB | |
| SCHEMBL189416 | 0.80 | HRH3 (0.54) | HRH3SMN1; SMN2CHRM4CHRM5CHRM1 | |
| SCHEMBL24596865 | 0.80 | HRH3 (0.54) | HRH3SMN1; SMN2CHRM4CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318006-B1 | NOVEL PYRROLE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE AS THERAPEUTIC AGENTS | NIVALIS THERAPEUTICS INC (US) | 2016-10-12 | — | — | EP | disclosed |
| US-9138427-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents | NIVALIS THERAPEUTICS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20140194425-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | N30 PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
| EP-2401281-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010098367-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |
| EP-1689393-A4 | PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-12-17 | — | — | EP | disclosed |
| US-20070123561-A1 | Preparation of 1,7-disubstituted azabensimidazoles as kinase inhibitors | LEE DENNIS | 2007-05-31 | — | — | US | disclosed |
| EP-1689393-A2 | PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005037198-A2 | PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194425-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | GSR, DHFR, GRHPR | HRH3 4711/4885SMN1; SMN2 4514/4885CHRM4 4548/4885 |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | WEE1, WEE2, DCK | HRH3 1505/4885SMN1; SMN2 4848/4885CHRM4 3680/4885 |
| US-20070123561-A1 | Preparation of 1,7-disubstituted azabensimidazoles as kinase inhibitors | TNK2, CDC42BPB, CDC42BPA | HRH3 2605/4885SMN1; SMN2 3537/4885CHRM4 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.